UPDATE 1-U.S. lawmakers want health agencies to lower prostate cancer drug cost
March 28 (Reuters) - A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc's and Astellas Pharma Inc's prostate cancer drug Xtandi.
No comments:
Post a Comment